ERK5 also plays a role in mediating drug resistance, with the combined inhibition of the PI3k/Akt and MEK5/ERK5 pathways reducing the viability of tamoxifen-resistant breast cancer cells [74]. The gene discussed is MAP2K5; the disease is breast carcinoma.